Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117

Benzinga · 2d ago
Leerink Partners analyst David Risinger downgrades Halozyme Therapeutics (NASDAQ:HALO) from Outperform to Market Perform and raises the price target from $110 to $117.